High rate of colistin and fosfomycin resistance among carbapenemase-producing Enterobacteriaceae in Turkey by Süzük Yıldız, Serap et al.
HIGH RATE OF COLISTIN AND FOSFOMYCIN
RESISTANCE AMONG CARBAPENEMASE-
PRODUCING ENTEROBACTERIACEAE IN TURKEY
SERAP SÜZÜK YILDIZ1*, BANU KAŞKATEPE2, HÜSNİYE ŞİMŞEK1 and
FATMA MUTLU SARIGÜZEL3
1Department of National AMR Surveillance Laboratory, Public Health Microbiology
Reference Laboratories, Ministry of Health, Ankara, Turkey
2Faculty of Pharmacy, Department of Pharmaceutical Microbiology,
Ankara University, Ankara, Turkey
3Department of Clinical Microbiology, Ankara Training and Research Hospital,
Ankara, Turkey
(Received: 6 August 2018; accepted: 5 September 2018)
When the problem with carbapenem-resistant Enterobacteriaceae (CRE)
increases, the older antimicrobial agents such as colistin and fosfomycin are used
for the treatment of these infections. In this study, the broth microdilution method for
colistin and the agar dilution method for fosfomycin were used for a total of
147 multidrug-resistant (MDR) or extensively drug-resistant (XDR) strains of CRE.
The study included Klebsiella pneumoniae (91.16%), Escherichia coli (7.48%),
Enterobacter cloacae (0.68%), and Serratia marcescens (0.68%). All these strains
produce various types of carbapenemase, including OXA-48, NDM, and KPC.
Some of these strains also have three different carbapenemase mechanisms, including
OXA-48 (78.23%), NDM (2.04%), and KPC (0.68%) or OXA-48 and NDM
(10.88%), or OXA-48 and KPC (0.68%). About 76.19% of the strains and
67.35% of the strains were resistant for colistin and fosfomycin, respectively. A total
of 21 out of 35 colistin-susceptible strains were found to be susceptible to fosfomycin.
This study showed that the resistance rates of colistin and fosfomycin are high. The
MDR and XDR strains of CRE are spreading in our region and thus a monitoring
system for CRE should be followed. Moreover, the applicability of antimicrobial
stewardship programs should be increased in all inpatient and outpatient settings.
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Introduction
The strains of carbapenem-resistant Enterobacteriaceae (CRE) are a serious
threat to public health with a rapid spread worldwide. The carbapenemases
identiﬁed in Enterobacteriaceae are Klebsiella pneumoniae carbapenemase
(KPC), the metallo-β-lactamases such as New Delhi metallo-β-lactamase (NDM),
Verona integron-encoded metallo-β-lactamase, and imipenemase as well as
OXA-48. All these enzymes hydrolyze penicillins and imipenem, sparing the
broad-spectrum cephalosporins [1]. According to the data of the Central Asian and
Eastern European Surveillance of Antimicrobial Resistance (CAESAR), the
carbapenem resistance rates of Escherichia coli and K. pneumoniae, isolated
from blood culture in Turkey in the year 2016, were 5% and 35%, respectively [2].
In Istanbul, Turkey, the Ambler class D β-lactamase OXA-48 was initially
identiﬁed from a carbapenem-resistant isolate of K. pneumoniae. In our country,
β-lactamase OXA-48 is the most common carbapenemase, but recently, the
association between OXA-48 and NDM-1 has been reported frequently [3, 4].
An important feature of the CRE is their resistance to multiple antibiotics. As a
result, the treatment options with antibiotics are limited for these multidrug-resistant
infections. Newer treatment options with antibiotics are very limited in the multidrug-
resistant Gram-negative bacteria. The old antibiotics such as colistin and fosfomycin
are frequently used in the treatment of these isolates worldwide [5]. Colistin
(polymyxin E) is one of the oldest antibiotics that affect the outer cell membrane
of the Gram-negative bacilli by binding to the lipid A component of the lipopolysac-
charide layer. The antibacterial spectrum of colistin includes most members of the
Enterobacteriaceae family. Another old antibiotic is fosfomycin that inhibits bacterial
cell wall synthesis [6]. In Turkey, colistin is used for the treatment of the multidrug-
resistant strains of CRE by either monotherapy or combination therapy [7]. Although
the intravenous formulation of fosfomycin (fosfomycin disodium) is not available in
Turkey, its use in the treatment of CRE has been reported to be quite safe [8].
Given the increase in CRE and multidrug resistance, this study was aimed to
evaluate the frequency of colistin and fosfomycin resistance in CRE by the
reference methods.
Materials and Methods
Settings and study design
This was a prospective study that included consecutive inpatients of any age
and sex, having an infection with any CRE in the period between January 2017
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and June 2018. During this period, a total of 147 strains of CRE, referred to outside
reference laboratories, were isolated from blood, urine, and tracheal aspirate.
Using standard microbiology laboratory techniques, the clinical samples were
analyzed. Only one isolate per patient was included. All the bacterial isolates were
identiﬁed by matrix-assisted laser desorption ionization time of ﬂight/mass
spectrometry (Bruker MALDI Biotyper; Bruker Daltonics; Bremen, Germany).
Phenotypic extended-spectrum beta-lactamase (ESBL), ampicillin (AmpC), and
carbapenemase tests
Antibiotic susceptibility tests were conducted and the ESBLs from the
isolates were analyzed by the BD Phoenix automated system (BD Diagnostics,
Sparks, MD). Meropenem disks (10 μg) were used to screen the carbapenem
resistance in all the isolates. If the diameter of the disk zones was found
to be <28 mm, the production of carbapenemase was investigated [9]. ESBL,
AmpC, and carbapenemase were tested using the phenotypical Mast D68C
AmpC + ESBL Detection Set and the Mast D70C Carbapenemase Detection
Set (Mast Diagnostics, UK). The Mastdisks ID inhibitor combination disks
(Mast Diagnostics) method was performed according to the manufacturer’s
instructions.
Detection of the genes for resistance to carbapenem
The blaKPC, blaOXA-48, and blaNDM-1 genes were detected in the isolates by
the polymerase chain reaction method, displaying a reduced sensitivity against
meropenem [3, 10–13].
Determination of the minimum inhibitory concentration (MIC) value for colistin
by the broth microdilution method
The MIC value for colistin was determined by the broth microdilution
method, using the cation-adjusted Mueller–Hinton broth (Oxoid, Code:
CM0405, UK), according to the ISO Standard 20776–1:2006 [14]. Colistin
sulfate (Sigma-Aldrich, St. Louis, MO) was tested over a range of dilutions
(0.06–64 μg/ml). An amount of 50 μl of the different concentrations of freshly
prepared antibiotics was added to 96-well U-bottom microplates. Bacterial
suspensions, prepared from the bacteria, grown in non-selective culture media,
were added to the microplates. The microplates were then incubated at 37 °C
for 24 h in ambient air. The breakpoints of the European Committee on
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Antimicrobial Susceptibility Testing (EUCAST) were used as references for
comparing the results (susceptible ≤2 mg/L; resistant >2 mg/L) [15].
Determination of the MIC value for fosfomycin by the agar dilution method
The agar dilution method was performed according to the guidelines of the
Clinical and Laboratory Standards Institute [16]. Mueller–Hinton agar plates
(Oxoid, UK) containing 25 mg/L glucose-6-phosphate and fosfomycin at con-
centrations ranging from 0.25 to 1.28 mg/L were prepared and then an inoculum of
104 CFU/ml was introduced onto the agar plates by a multipoint inoculator and
allowed to dry. The agar plates were then incubated at 35 °C for 16–20 h. After
incubation, the MIC value was determined as the lowest concentration without any
visible growth. The breakpoints of the EUCAST were used as the references for
comparing the results (susceptible ≤32 mg/L; resistant >32 mg/L) [17].
E. coli ATCC 25922 and E. coli NCTC 13846 were used as quality control
strains for the broth microdilution and agar dilution methods.
Statistical analysis
Statistical analyses were performed using the SPSS™ software, version 21.0
(IBMCorp., New York, NY). The results are presented as descriptive statistics and
expressed in terms of relative frequency.
Results
A total of 147 CRE strains were evaluated in this study, which included
134 strains of K. pneumoniae (91.16%), 11 strains of E. coli (7.48%), 1 strain of
Enterobacter cloacae (0.68%), and 1 strain of Serratia marcescens (0.68%). The
ESBL and AmpC positivity rates of the CRE strains were 20.41% and 5.44%,
respectively. Only in one strain of E. coli, AmpC with loss of porin was observed.
The strains were positive for the carbapenemases, such as OXA-48, NDM-1,
and KPC. In addition, some of the isolates were positive for OXA-48 and NDM or
OXA-48 and KPC together. The positivity distributions are shown in Table I.
The rates of resistance to colistin and fosfomycin were found to be 76.19%
and 67.35%, respectively. A total of 87 out of 112 colistin-resistant strains
(59.18%) were found to be resistant to fosfomycin, whereas a total of 21 out
of 35 colistin-susceptible strains (60%) were found to be susceptible to fosfo-
mycin. Furthermore, a total of 20 out of 30 isolates positive for both ESBL and
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carbapenemase were found to be resistant to colistin and fosfomycin. Five AmpC
positive strains were resistant to both colistin and fosfomycin.
Susceptibility to colistin (MIC50 and MIC90 values)
A total of 112 out of 147 strains (76.19%) were found to be resistant to
colistin. The MIC values for colistin were determined by the broth microdilution
technique on all the strains. The MIC50 and MIC90 values for colistin were found
to be 32 and 64 mg/L, respectively.
Susceptibility to fosfomycin (MIC50 and MIC90 values)
A total of 99 out of 147 strains (67.35%) were found to be resistant to
fosfomycin. The agar dilution method was used to determine fosfomycin suscep-
tibility for all the strains. The MIC50 and MIC90 values for fosfomycin were found
to be 64 and 128 mg/L, respectively.
Discussion
The increase in the multidrug-resistant (MDR) and extensively drug-
resistant (XDR) strains of bacteria is a global issue. The limited availability of
new antibiotic options, the inadequate implementation of control measures for
infections, and the irrational usage of antibiotic policies further contribute to the
growth of this problem. The CAESAR data show that Turkey has a very high
number of resistant isolates, and a high percentage of these strains also have
multidrug resistance [2].
Despite their potential side effects, colistin and fosfomycin are known to
provide a therapeutic option for the MDR or XDR strains of Enterobacteriaceae.
This study showed very high resistance rates of 76.19% and 67.35% to colistin and
fosfomycin, respectively, among the MDR and XDR strains of Enterobacteriaceae.
The reason behind such high rates of resistance is that only the XDR and MDR
isolates were selected for this study. Moreover, a study on antibiotic consumption
among patients, hospitalized in Turkey, showed that 44.8% of them were
using antibiotics and the total antibiotic consumption was 674.5 deﬁned daily
dose/1000 patient-days [18]. Therefore, it is highly possible that a high rate of
resistance is associated with antibiotic consumption.
Although resistance to colistin by chromosomal mutations has been reported
earlier, the plasmid-mediated colistin resistance gene, mcr-1, and its variants and
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two other genes, mcr-1.2 and mcr-2, have been reported in recent years [19, 20].
Although the presence of the plasmid-mediated colistin resistance genes, mcr-1
andmcr-2, is not detected in Turkey, the resistance to colistin, a last-line antibiotic
against the infections of multidrug-resistant or carbapenem-resistant Gram-
negative bacteria, is too high [21].
The development of resistance to fosfomycin is similar to that of colistin. As
reported earlier, resistance to fosfomycin mainly occurs through chromosomal
mutations. Subsequently, the plasmid-mediated mechanisms of resistance to
fosfomycin have been described in the clinical strains of Gram-negative bacteria
[22]. An increase in the plasmid-mediated mechanisms of resistance further
increases the magnitude of this global problem of antibiotic resistance and thus
it is necessary to give importance to the studies that need to be carried out for the
monitoring and controlling of antibiotic resistance.
In a study conducted in a tertiary hospital in Pakistan, the rates of resistance
to colistin and fosfomycin among the strains of CRE were found to be 15.9% and
12.3%, respectively. In this study, the colistin susceptibility test was performed by
the broth microdilution technique and the fosfomycin susceptibility test was
performed by the disk diffusion method, using fosfomycin trometamol disks
[23]. EUCAST does not suggest using fosfomycin trometamol disks for the strains
of Enterobacteriaceae except for the urinary E. coli strains [9]. Fosfomycin has
been shown to be slightly less active, especially against the KPC-producing strains
ofK. pneumoniae [24]. In this study, two of the KPC-producing strains were found
to be resistant to fosfomycin.
In a study conducted in Germany in 2013, the susceptibility to fosfomycin,
using the agar dilution method was determined to be 78% with the MIC50 and
MIC90 values of 8 and 512 mg/L, respectively [25]. Such a difference in the rates
of resistance can be attributed to the MDR and XDR strains included in this study
and also to the rates of resistance in Turkey, which are higher than in Germany.
The MIC90 value for fosfomycin was found to be 128 mg/L, but it might be more
because the higher dilutions were not studied.
The carbapenemase, OXA-48, known to hydrolyze penicillins and carba-
penems possesses poor activity against the broad-spectrum cephalosporins.
Multidrug resistance in the OXA-48-producing strains often results from the
co-production of the various mechanisms of resistance, particularly the ESBLs and
other determinants of resistance [26]. In this study, the strains with ESBL or
AmpC positivity were found to be resistant to both colistin and fosfomycin,
whereas the rates of resistance to ESBL and AmpC were not found to be high.
We know that this study has a few limitations. We could not detect the genes
for resistance to colistin and fosfomycin due to ﬁnancial limitations. The other
limitation of this study was that only the MDR and XDR strains were included in
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the study and thus the resistance rate was found to be too high. The fact that higher
dilutions were not studied for the determination of MIC values could be another
important limitation of this study.
Conclusions
However, this study is the ﬁrst report on the susceptibility to colistin and
fosfomycin, as determined by the reference methods from Turkey. According to
the data obtained from this study, the use of colistin and fosfomycin does not seem
to be a promising therapeutic approach for the MDR and XDR strains of
Enterobacteriaceae in Turkey, and a regular monitoring system for the MDR
and XDR strains of CRE is needed. Moreover, in order to identify the susceptible
isolates, it should be ensured that the reference methods are applied in the
laboratory. If necessary, support should be taken from the reference or national
laboratories for the agar dilution and broth microdilution techniques.
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